Wellstar/TMI Announces Completion of HIPAA Compliance Guideline and Procedures

Wellstar International, Inc. (OTCBB: WLSI), a provider of specialized diagnostic software and equipment, today announced the completion of their Health Insurance Portability and Accountability Act ("HIPAA") compliance guideline and procedures. Wellstar's wholly-owned subsidiary, Trillennium Medical Imaging ("TMI"), has developed a fully calibrated and functional, thermal imaging system that utilizes state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body. TMI's primary application for their system is the early detection of pressure ulcers.

Wellstar and TMI have taken every step possible to ensure that all protected health information (known as Electronic Protected Health Information or EPHI), which is created, stored, transmitted or received electronically as a result of the Company's thermal imaging system being utilized by healthcare and long-term care facilities, is completely secure and encrypted -- which is achieved by assigning each patient a 30-digit numerical value and bar code through the use of TMI's proprietary software.

TMI's vice president of operations, Brian Brooks, stated: "By securing the identity of each patient, TMI can effectively and objectively compare and contrast all patterns of injury associated with the development of pressure ulcers, without compromising patient information. This will allow us to continue to gather valuable data that will help further define these markers."

ABOUT WELLSTAR INTERNATIONAL, INC.:

Wellstar International, Inc., through its wholly owned operating subsidiary Trillenium Medical Imaging, Inc. (TMI), is poised to become a leading diagnostic company in the health care industry. TMI has developed and is marketing fully calibrated and functional, thermal imaging systems that utilize state-of-the-art infrared technologies and proprietary software to accurately and cost-effectively measure physiological changes in the human body. More information on the Company and its unique diagnostic software and product line is available on Wellstar's corporate Website, by visiting: www.wellstar.us.

FORWARD-LOOKING STATEMENTS:

This press release contains statements, which may constitute 'forward-looking statements' within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.